AU2011239683A1 - Compositions and methods for treating visual disorders - Google Patents
Compositions and methods for treating visual disorders Download PDFInfo
- Publication number
- AU2011239683A1 AU2011239683A1 AU2011239683A AU2011239683A AU2011239683A1 AU 2011239683 A1 AU2011239683 A1 AU 2011239683A1 AU 2011239683 A AU2011239683 A AU 2011239683A AU 2011239683 A AU2011239683 A AU 2011239683A AU 2011239683 A1 AU2011239683 A1 AU 2011239683A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- substituted
- retinal
- oil
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 41
- 208000029257 vision disease Diseases 0.000 title claims description 5
- 208000013521 Visual disease Diseases 0.000 title description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 26
- 239000001257 hydrogen Substances 0.000 claims abstract description 26
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 25
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 125000005518 carboxamido group Chemical group 0.000 claims abstract description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract description 10
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 10
- 150000003456 sulfonamides Chemical class 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 125000005415 substituted alkoxy group Chemical group 0.000 claims abstract description 5
- 125000004426 substituted alkynyl group Chemical group 0.000 claims abstract description 5
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims abstract description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 5
- 230000000007 visual effect Effects 0.000 claims description 19
- 210000000857 visual cortex Anatomy 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 230000027928 long-term synaptic potentiation Effects 0.000 claims description 16
- 208000017442 Retinal disease Diseases 0.000 claims description 15
- 230000002207 retinal effect Effects 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 12
- 208000002367 Retinal Perforations Diseases 0.000 claims description 10
- 208000029977 White Dot Syndromes Diseases 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 206010038923 Retinopathy Diseases 0.000 claims description 8
- -1 benzo[1,2,5]oxadiazol-5-yl Chemical group 0.000 claims description 8
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 8
- 239000003981 vehicle Substances 0.000 claims description 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- XFVRBYKKGGDPAJ-UHFFFAOYSA-N farampator Chemical compound C1=CC2=NON=C2C=C1C(=O)N1CCCCC1 XFVRBYKKGGDPAJ-UHFFFAOYSA-N 0.000 claims description 7
- 201000004569 Blindness Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010038848 Retinal detachment Diseases 0.000 claims description 6
- 206010046851 Uveitis Diseases 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 210000001525 retina Anatomy 0.000 claims description 6
- 230000004264 retinal detachment Effects 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 201000009487 Amblyopia Diseases 0.000 claims description 5
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 208000014882 Carotid artery disease Diseases 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 claims description 4
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 4
- 206010038897 Retinal tear Diseases 0.000 claims description 4
- 206010038910 Retinitis Diseases 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 208000027073 Stargardt disease Diseases 0.000 claims description 4
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 235000005687 corn oil Nutrition 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000006379 syphilis Diseases 0.000 claims description 4
- 230000001982 uveitic effect Effects 0.000 claims description 4
- 206010005177 Blindness cortical Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 3
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 201000008615 cone dystrophy Diseases 0.000 claims description 3
- 208000009153 cortical blindness Diseases 0.000 claims description 3
- 201000011190 diabetic macular edema Diseases 0.000 claims description 3
- 230000001037 epileptic effect Effects 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 210000000977 primary visual cortex Anatomy 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 claims description 2
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 claims description 2
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 208000005598 Angioid Streaks Diseases 0.000 claims description 2
- 235000003911 Arachis Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 235000005747 Carum carvi Nutrition 0.000 claims description 2
- 240000000467 Carum carvi Species 0.000 claims description 2
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 2
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010070957 Choroidal haemangioma Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- 208000002691 Choroiditis Diseases 0.000 claims description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 2
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 208000019878 Eales disease Diseases 0.000 claims description 2
- 208000001351 Epiretinal Membrane Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 208000002927 Hamartoma Diseases 0.000 claims description 2
- 201000002563 Histoplasmosis Diseases 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 206010058558 Hypoperfusion Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 206010022557 Intermediate uveitis Diseases 0.000 claims description 2
- 206010022941 Iridocyclitis Diseases 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 206010025412 Macular dystrophy congenital Diseases 0.000 claims description 2
- 208000035719 Maculopathy Diseases 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000009857 Microaneurysm Diseases 0.000 claims description 2
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims description 2
- 208000006123 Myiasis Diseases 0.000 claims description 2
- 206010065119 Necrotising herpetic retinopathy Diseases 0.000 claims description 2
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims description 2
- 206010065700 Ocular sarcoidosis Diseases 0.000 claims description 2
- 206010065373 Papillophlebitis Diseases 0.000 claims description 2
- 208000004788 Pars Planitis Diseases 0.000 claims description 2
- 208000034247 Pattern dystrophy Diseases 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002675 Polyoxyl Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 208000003971 Posterior uveitis Diseases 0.000 claims description 2
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 claims description 2
- 206010064714 Radiation retinopathy Diseases 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims description 2
- 201000001949 Retinal Vasculitis Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 2
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 claims description 2
- 206010038915 Retinitis viral Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 208000014286 Serpiginous choroiditis Diseases 0.000 claims description 2
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 claims description 2
- 208000036038 Subretinal fibrosis Diseases 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 206010043189 Telangiectasia Diseases 0.000 claims description 2
- 206010044269 Toxocariasis Diseases 0.000 claims description 2
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 claims description 2
- 208000017441 X-linked retinoschisis Diseases 0.000 claims description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 208000023564 acute macular neuroretinopathy Diseases 0.000 claims description 2
- 208000019672 acute posterior multifocal placoid pigment epitheliopathy Diseases 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 229920006321 anionic cellulose Polymers 0.000 claims description 2
- 239000010617 anise oil Substances 0.000 claims description 2
- 201000004612 anterior uveitis Diseases 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 206010072959 birdshot chorioretinopathy Diseases 0.000 claims description 2
- 208000015294 blood coagulation disease Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 201000005845 branch retinal artery occlusion Diseases 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 201000005849 central retinal artery occlusion Diseases 0.000 claims description 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 208000027129 choroid disease Diseases 0.000 claims description 2
- 239000010630 cinnamon oil Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 239000010634 clove oil Substances 0.000 claims description 2
- 208000006623 congenital stationary night blindness Diseases 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- 201000010206 cystoid macular edema Diseases 0.000 claims description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 2
- 229940124274 edetate disodium Drugs 0.000 claims description 2
- 206010014801 endophthalmitis Diseases 0.000 claims description 2
- 239000010642 eucalyptus oil Substances 0.000 claims description 2
- 229940044949 eucalyptus oil Drugs 0.000 claims description 2
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 229940089456 isopropyl stearate Drugs 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 2
- 208000029233 macular holes Diseases 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000002165 neuroretinitis Diseases 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 208000008940 ocular tuberculosis Diseases 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 235000019477 peppermint oil Nutrition 0.000 claims description 2
- 229940096826 phenylmercuric acetate Drugs 0.000 claims description 2
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 125000001095 phosphatidyl group Chemical group 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000000649 photocoagulation Effects 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 201000004849 posterior scleritis Diseases 0.000 claims description 2
- 201000002267 posterior uveal melanoma Diseases 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 claims description 2
- 208000034503 punctate inner choroidopathy Diseases 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 201000007714 retinoschisis Diseases 0.000 claims description 2
- 239000010668 rosemary oil Substances 0.000 claims description 2
- 229940058206 rosemary oil Drugs 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 229940001474 sodium thiosulfate Drugs 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 230000003074 vasoproliferative effect Effects 0.000 claims description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 claims 1
- 208000007333 Brain Concussion Diseases 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 5
- 102000003678 AMPA Receptors Human genes 0.000 description 4
- 108090000078 AMPA Receptors Proteins 0.000 description 4
- 229920006318 anionic polymer Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000007585 cortical function Effects 0.000 description 2
- 230000000848 glutamatergic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001777 nootropic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000009782 synaptic response Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- JUMYIBMBTDDLNG-UHFFFAOYSA-N methylphenidate hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C(=O)OC)C1CCCC[NH2+]1 JUMYIBMBTDDLNG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003389 pramiracetam Drugs 0.000 description 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 1
- 230000004256 retinal image Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32463210P | 2010-04-15 | 2010-04-15 | |
| US61/324,632 | 2010-04-15 | ||
| PCT/US2011/032325 WO2011130411A1 (en) | 2010-04-15 | 2011-04-13 | Compositions and methods for treating visual disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2011239683A1 true AU2011239683A1 (en) | 2012-11-08 |
Family
ID=44009992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011239683A Abandoned AU2011239683A1 (en) | 2010-04-15 | 2011-04-13 | Compositions and methods for treating visual disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110257186A1 (https=) |
| EP (1) | EP2558100A1 (https=) |
| JP (1) | JP2013523892A (https=) |
| KR (1) | KR20130092976A (https=) |
| AU (1) | AU2011239683A1 (https=) |
| CA (1) | CA2796345A1 (https=) |
| RU (1) | RU2012148214A (https=) |
| WO (1) | WO2011130411A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600127037A1 (it) * | 2016-12-15 | 2018-06-15 | Oftalab S R L | Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia |
| CN109908327A (zh) * | 2019-03-12 | 2019-06-21 | 广州陈锦济生物科技有限公司 | 一种用于治疗近视的眼药水及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| KR20050094840A (ko) * | 2003-01-13 | 2005-09-28 | 코텍스 파마슈티칼스, 인크. | 수면 부족 및 스트레스로 인한 인식 저하의 치료방법 |
| WO2007124348A2 (en) * | 2006-04-20 | 2007-11-01 | The Regents Of The University Of California | Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression |
| WO2008060375A2 (en) * | 2006-10-06 | 2008-05-22 | The Regents Of The University Of Californina | Upregulating bdnf levels to mitigate mental retardation |
| BRPI0720323A2 (pt) | 2007-01-03 | 2016-08-09 | Cortex Pharma Inc | composto, método de tratamento, composição farmacêutica e uso do composto |
| GEP20125438B (en) * | 2007-01-03 | 2012-03-26 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| KR20100063087A (ko) * | 2007-09-20 | 2010-06-10 | 코텍스 파마슈티칼스, 인크. | 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논 |
-
2011
- 2011-04-12 US US13/085,241 patent/US20110257186A1/en not_active Abandoned
- 2011-04-13 CA CA2796345A patent/CA2796345A1/en not_active Abandoned
- 2011-04-13 AU AU2011239683A patent/AU2011239683A1/en not_active Abandoned
- 2011-04-13 EP EP11715842A patent/EP2558100A1/en not_active Withdrawn
- 2011-04-13 RU RU2012148214/15A patent/RU2012148214A/ru not_active Application Discontinuation
- 2011-04-13 KR KR1020127029867A patent/KR20130092976A/ko not_active Withdrawn
- 2011-04-13 WO PCT/US2011/032325 patent/WO2011130411A1/en not_active Ceased
- 2011-04-13 JP JP2013505098A patent/JP2013523892A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110257186A1 (en) | 2011-10-20 |
| WO2011130411A1 (en) | 2011-10-20 |
| KR20130092976A (ko) | 2013-08-21 |
| CA2796345A1 (en) | 2011-10-20 |
| RU2012148214A (ru) | 2014-05-20 |
| JP2013523892A (ja) | 2013-06-17 |
| EP2558100A1 (en) | 2013-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7519413B2 (ja) | 眼科用薬剤組成物、眼科用キット、及びその医学的応用 | |
| JP2010536797A5 (https=) | ||
| JP2009511632A5 (https=) | ||
| RS63136B9 (sr) | Lekoviti sastav koji sadrži tivozanib | |
| US20090118262A1 (en) | Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery | |
| JP2017503028A (ja) | 眼内血管新生及び／または漏出を治療するための組成物及び方法 | |
| US20170172959A1 (en) | D-serine for the treatment of visual system disorders | |
| US20110257186A1 (en) | Compositions and methods for treating visual disorders | |
| JP2019534269A5 (https=) | ||
| KR20070051768A (ko) | 레티노이드를 사용한 광수용체 변성의 방지 및/또는 감소 | |
| JP2013501794A (ja) | 目の疾患を治療するためのイソチオゾール | |
| JP2002356431A (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
| CN111358751B (zh) | 眼用药物组合物、眼用药盒及其医药用途 | |
| US20130197002A1 (en) | Brimonidine for treating visual disorders mediated by central visual projections from the eye | |
| CA3036474C (en) | Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor | |
| US20130267488A1 (en) | Pharmaceutical formulation having neuroprotective activity | |
| KR20070018755A (ko) | 무스카린 수용체 작동약을 함유한 안과용 경피흡수형 제제 | |
| CN117355292A (zh) | 用于预防或治疗眼病的抑制n-氧代吡啶化合物出现的眼科组合物 | |
| HK40074896A (en) | Ophthalmic pharmaceutical composition, ophthalmic kit, and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |